A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
Authors: El-Khoueiry AB; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Medical College at Cornell University, New York, NY, USA.; Trinity College Dublin, Dublin, Ireland., Tsimberidou AM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahadevan D; The University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA., Hanna DL; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Bockorny B; Beth Israel Deaconess Medical Center, Boston, MA, USA., Wilky BA; University of Colorado Cancer Center, Aurora, CO, USA., Leal A; University of Colorado Cancer Center, Aurora, CO, USA., Stebbing J; Anglia Ruskin University, Cambridge, UK., Avagyan M; Agenus Inc, Lexington, MA, USA., Wu W; Agenus Inc, Lexington, MA, USA., Chand D; Agenus Inc, Lexington, MA, USA., Grossman JE; Agenus Inc, Lexington, MA, USA., Johnson B; Agenus Inc, Lexington, MA, USA., Bullock AJ; Beth Israel Deaconess Medical Center, Boston, MA, USA.
Source: Liver cancer [Liver Cancer] 2026 Mar 30. Date of Electronic Publication: 2026 Mar 30.
Publication Type: Journal Article
Journal Info: Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer
Database: MEDLINE Ultimate
Description
ISSN:2235-1795
DOI:10.1159/000551630